NO910811L - Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper. - Google Patents

Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.

Info

Publication number
NO910811L
NO910811L NO91910811A NO910811A NO910811L NO 910811 L NO910811 L NO 910811L NO 91910811 A NO91910811 A NO 91910811A NO 910811 A NO910811 A NO 910811A NO 910811 L NO910811 L NO 910811L
Authority
NO
Norway
Prior art keywords
zymogens
variants
zymogenic
plasminogen activator
tissue plasminogen
Prior art date
Application number
NO91910811A
Other languages
English (en)
Other versions
NO310778B1 (no
NO910811D0 (no
Inventor
Stephen Anderson
William F Bennett
David Botstein
Deborah L Higgins
Nicholas F Paoni
Mark Zoller
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO910811L publication Critical patent/NO910811L/no
Publication of NO910811D0 publication Critical patent/NO910811D0/no
Publication of NO310778B1 publication Critical patent/NO310778B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO19910811A 1988-09-02 1991-02-28 Fremgangsmåte for fremstilling av vevsplasminogen-aktivator med zymogeniske eller fibrinspesifikke egenskaper NO310778B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24085688A 1988-09-02 1988-09-02
US07/384,608 US5108901A (en) 1988-09-02 1989-07-24 Tissue plasminogen activator having zymogenic or fibrin specific properties
PCT/US1989/003755 WO1990002798A1 (en) 1988-09-02 1989-08-29 Tissue plasminogen activator having zymogenic or fibrin specific properties

Publications (3)

Publication Number Publication Date
NO910811L true NO910811L (no) 1991-02-28
NO910811D0 NO910811D0 (no) 1991-02-28
NO310778B1 NO310778B1 (no) 2001-08-27

Family

ID=26933781

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19910811A NO310778B1 (no) 1988-09-02 1991-02-28 Fremgangsmåte for fremstilling av vevsplasminogen-aktivator med zymogeniske eller fibrinspesifikke egenskaper

Country Status (18)

Country Link
US (1) US5108901A (no)
EP (1) EP0457758B1 (no)
JP (1) JP2794028B2 (no)
KR (1) KR0148575B1 (no)
AT (1) ATE124452T1 (no)
AU (1) AU626323B2 (no)
CA (1) CA1341484C (no)
DE (1) DE68923298T2 (no)
DK (1) DK175958B1 (no)
ES (1) ES2018729A6 (no)
FI (1) FI109359B (no)
HK (1) HK1007334A1 (no)
HU (1) HU213922B (no)
IE (1) IE67508B1 (no)
IL (1) IL91306A (no)
NO (1) NO310778B1 (no)
NZ (1) NZ230509A (no)
WO (1) WO1990002798A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736134A (en) * 1985-04-22 1998-04-07 Genentech, In.C Tissue plasminogen activator variants
US5756093A (en) * 1985-04-22 1998-05-26 Genentech, Inc. Tissue plasminogen activator variants
GB8815135D0 (en) * 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5156969A (en) * 1988-09-02 1992-10-20 Genentech Inc. Tissue plasminogen activator variant with deletion of amino acids 466-470 having fibrin specific properties
US5866413A (en) * 1989-03-06 1999-02-02 Board Of Regents Of The University Of Texas System Pai-1 mutants
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5550042A (en) * 1989-03-06 1996-08-27 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors and genes encoding the same and serine protease inhibitor mutants and genes encoding the same
CA2047702C (en) * 1989-03-06 2000-10-24 Joseph F. Sambrook Serpin resistant chymotrypsin superfamily proteases particularly pai-1 resistant t-pa, complementary inhibitor mutants; compositions; genes; expression
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
US5472692A (en) * 1993-07-02 1995-12-05 New England Deaconess Hospital Corporation Pro-urokinase mutants
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5656427A (en) * 1994-08-29 1997-08-12 Gen-Probe Incorporated Nucleic acid hybridization assay probes, helper probes and amplification oligonucleotides targeted to Mycoplasma pneumoniae nucleic acid
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
CN1244894A (zh) * 1996-11-12 2000-02-16 斯克里普斯研究所 组织型纤溶酶原活化剂(t－PA)变体:组合物及使用方法
US6706504B1 (en) 1996-11-12 2004-03-16 The Scripps Research Institute Tissue type plasminogen activator (t-PA) variants: compositions and methods of use
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
DE69737457T2 (de) 1997-01-31 2007-11-29 Genentech, Inc., South San Francisco O-fukosyltransferase
AU8864398A (en) * 1997-08-13 1999-03-08 Boehringer Mannheim Gmbh Plasminogen activator with enhanced zymogenic power and reduced fibrin linking
WO1999009185A1 (de) * 1997-08-13 1999-02-25 Roche Diagnostics Gmbh Plasminogenaktivator mit verbesserter zymogenität
KR100408844B1 (ko) * 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
WO2006023530A2 (en) * 2004-08-16 2006-03-02 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
CA2650140A1 (en) * 2006-04-14 2007-10-25 Mriganka Sur Identifying and modulating molecular pathways that mediate nervous system plasticity
EP2056852A4 (en) * 2006-07-27 2010-01-13 Centocor Ortho Biotech Inc BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
WO2016073514A2 (en) 2014-11-03 2016-05-12 Thrombolytic Science, Llc Methods and compositions for safe and effective thrombolysis
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0125269A1 (en) * 1982-11-11 1984-11-21 Beecham Group Plc Pharmaceutically active compounds
EP0112122B1 (en) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Plasminogen activator
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
DK175380B1 (da) * 1985-04-22 2004-09-20 Genentech Inc Mutant af human vævsplasminogenaktivator, DNA-sekvens som koder herfor, replicerbar udtrykkelsesvektor til at udtrykke denne DNA-sekvens, mikroorganisme transformeret med denne vektor, cellekulturer transformeret med denne....
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
AU605124B2 (en) * 1985-12-23 1991-01-10 Behringwerke Aktiengesellschaft Novel peptide plasminogen activators
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
JP2527454B2 (ja) * 1986-01-31 1996-08-21 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新しい血栓溶解タンパク質
IE81073B1 (en) * 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
DK345087A (da) * 1986-07-11 1988-01-12 Novo Industri As Modificeret vaevsplasminogenaktivator
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
EP0292009A1 (en) * 1987-05-22 1988-11-23 Zymogenetics, Inc. Fibrinolytic proteins
ZA883958B (en) * 1987-06-04 1989-07-26 Zymogenetics Inc Mutant t-pa with ringle replacement
NO179874C (no) * 1987-06-04 1997-01-02 Zymogenetics Inc Fremgangsmåte for fremstilling av en t-PA-analog, DNA-sekvens som koder for t-PA-analogen, samt ekspresjonsvektor omfattende DNA-sekvensen og vertcelle omfattende denne
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
KR960015610B1 (ko) * 1987-06-22 1996-11-18 제네틱스 인스티튜트, 인코포레이티드 신규의 혈전붕괴 단백질의 제조방법
WO1989000191A1 (en) * 1987-07-06 1989-01-12 Genetics Institute, Inc. Novel thrombolytic proteins
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner

Also Published As

Publication number Publication date
IE67508B1 (en) 1996-04-03
DE68923298D1 (de) 1995-08-03
FI109359B (fi) 2002-07-15
KR0148575B1 (ko) 1998-10-15
AU4194689A (en) 1990-04-02
ATE124452T1 (de) 1995-07-15
JP2794028B2 (ja) 1998-09-03
EP0457758A1 (en) 1991-11-27
WO1990002798A1 (en) 1990-03-22
IL91306A (en) 1997-08-14
IL91306A0 (en) 1990-03-19
DK36991D0 (da) 1991-03-01
DK175958B1 (da) 2005-08-29
IE892650L (en) 1990-03-02
EP0457758B1 (en) 1995-06-28
CA1341484C (en) 2005-05-24
US5108901A (en) 1992-04-28
HUT58812A (en) 1992-03-30
HU213922B (en) 1997-11-28
AU626323B2 (en) 1992-07-30
JPH04500157A (ja) 1992-01-16
HU896005D0 (en) 1991-07-29
DE68923298T2 (de) 1996-01-11
KR900702019A (ko) 1990-12-05
NO310778B1 (no) 2001-08-27
ES2018729A6 (es) 1991-05-01
DK36991A (da) 1991-05-02
NZ230509A (en) 1991-06-25
NO910811D0 (no) 1991-02-28
FI911049A0 (fi) 1991-03-01
HK1007334A1 (en) 1999-04-09

Similar Documents

Publication Publication Date Title
NO910811D0 (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
Serrano The long road of research on snake venom serine proteinases
Toombs Alfimeprase: pharmacology of a novel fibrinolytic metalloproteinase for thrombolysis
Matsuda et al. A simple, large scale method for preparation of plasminogen-free fibrinogen
Ahmed et al. Biochemical characteristics of fibrolase, a fibrinolytic protease from snake venom
Silverstein et al. Thrombospondin-plasminogen interactions: modulation of plasmin generation
Paoni et al. Involvement of residues 296–299 in the enzymatic activity of tissue-type plasminogen activator
DK0517756T3 (da) Vævs-plasminogenaktivator med fibrinspecifikke egenskaber
Markland Fibrin (ogen) olytic enzymes from snake venoms
Bachmann Fibrinolytic agents
Gardell The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk
Lucena et al. Degradation of extracellular matrix proteins (fibronectin, vitronectin and laminin) by serine-proteinases isolated from Lonomia achelous caterpillar hemolymph
Torres et al. Bmoo FIBMP‐I: A New Fibrinogenolytic Metalloproteinase from Bothrops moojeni Snake Venom
Guerrero et al. Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model
Deguchi et al. Plasminogen activation by tissue plasminogen activator in the presence of platelets
Bode et al. New developments in thrombolytic therapy
DK0542869T3 (da) Vævsplasminogenaktivatorvarianter med nedsat udskillelse
EP0487660B1 (en) Treatment of thrombotic events
ATE114170T1 (de) Substitutionsvariante des gewebeplasminogenaktivators.
Loscalzo Fibrinolytic therapy
EP0326013A3 (en) Novel proteins derived from human alpha2-plasmin inhibitor or proteins similar thereto
DE69215537D1 (de) t-PA SUBSTITUTIONSVARIANTEN MIT VERBESSERTER FIBRINSPEZIFITÄT
Runge New horizons in the treatment of coronary artery thrombosis
Stewart Interactions of vampire bat plasminogen activator, tissue-type plasminogen activator, and TNK-variants with fibrin, fibrinogen, and the fibrin fragment (DD) E
Siigur et al. Polypeptides and proteins active in the coagulation process

Legal Events

Date Code Title Description
MK1K Patent expired